Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 108419, 6 pages
http://dx.doi.org/10.1155/2014/108419
Editorial

Diabetes Mellitus

12nd Medical Department and Diabetes Centre, NIMTS Hospital, 12 Monis Petraki, 11521 Athens, Greece
2Department of Diabetes, Saint Bartholomew's Hospital, University of London and Bizard Institute, EC1A 7BE London, UK
3Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece
4Department of Endocrinology, Diabetology and Nutrition, Jean Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, CINFO, 93140 Bondy, France
5Division of Experimental Diabetes and Aging, Mount Sinai School of Medicine, 1 Gustave L, Levy Place, P.O. Box 1460, New York City, NY 10029, USA

Received 28 November 2013; Accepted 28 November 2013; Published 23 January 2014

Copyright © 2014 Ilias Migdalis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Papanas, N. Katsiki, Z. Putz, and D. P. Mikhailidis, “Diabetes, obesity and vascular disease—an update,” Current Pharmaceutical Design, vol. 19, no. 27, pp. 4900–4903, 2013. View at Publisher · View at Google Scholar
  2. R. Villegas, Y.-B. Xiang, T. Elasy et al., “Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women,” American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 543–551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Djoussé, J. M. Gaziano, J. E. Buring, and I.-M. Lee, “Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes,” American Journal of Clinical Nutrition, vol. 93, no. 1, pp. 143–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” Endocrine Reviews, vol. 26, no. 3, pp. 439–451, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Frystyk, L. Tarnow, T. Krarup Hansen, H.-H. Parving, and A. Flyvbjerg, “Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications,” Diabetologia, vol. 48, no. 9, pp. 1911–1918, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Khaodhiar, P.-R. Ling, G. L. Blackburn, and B. R. Bistrian, “Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity,” Journal of Parenteral and Enteral Nutrition, vol. 28, no. 6, pp. 410–415, 2004. View at Google Scholar · View at Scopus
  7. G. Mavridis, E. Souliou, E. Diza et al., “Inflammatory cytokines in insulin-treated patients with type 2 diabetes,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 7, pp. 471–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Maldonado, C. S. Hampe, L. K. Gaur et al., “Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and β-cell functional classification, prospective analysis, and clinical outcomes,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5090–5098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Zhang, J. Zhang, X. Yang, and X. Han, “Several transcription factors regulate COX-2 gene expression in pancreatic β-cells,” Molecular Biology Reports, vol. 34, no. 3, pp. 199–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetologia, vol. 55, no. 6, pp. 1577–1596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Papanas and E. Maltezos, “Antidiabetic treatment: though lovers be lost, love shall not,” World Journal of Diabetes, vol. 3, no. 9, pp. 158–160, 2012. View at Publisher · View at Google Scholar
  12. E. W. Gregg, H. Chen, L. E. Wagenknecht et al., “Association of an intensive lifestyle intervention with remission of type 2 diabetes,” Journal of the American Medical Association, vol. 308, no. 23, pp. 2489–2496, 2012. View at Publisher · View at Google Scholar
  13. P. R. Schauer, S. R. Kashyap, K. Wolski et al., “Bariatric surgery versus intensive medical therapy in obese patients with diabetes,” The New England Journal of Medicine, vol. 366, no. 17, pp. 1567–1576, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. C. Satchell and J. E. Tooke, “What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?” Diabetologia, vol. 51, no. 5, pp. 714–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. V. Schwartz, D. E. Sellmeyer, E. Vittinghoff et al., “Thiazolidinedione use and bone loss in older diabetic adults,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3349–3354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Ceriello, F. Cremasco, E. Romoli, A. Rossi, and R. Gentilella, “Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data,” Expert Opinion on Pharmacotherapy, vol. 13, no. 2, pp. 255–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. E. R. Mathiesen, M. Hod, M. Ivanisevic et al., “Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes,” Diabetes Care, vol. 35, no. 10, pp. 2012–2017, 2012. View at Publisher · View at Google Scholar
  18. A. M. de Vos, M. Prokop, C. J. Roos et al., “Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women,” European Heart Journal, vol. 29, no. 6, pp. 777–783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Papanas, E. Maltezos, and M. Edmonds, “Salvation of the diabetic foot: still a quest for the holy grail?” Vasa, vol. 40, no. 4, pp. 267–269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. M. Boulton, “The diabetic foot: grand overview, epidemiology and pathogenesis,” Diabetes/Metabolism Research and Reviews, vol. 24, supplement 1, pp. S3–S6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Demetriou, N. Papanas, M. Panopoulou, K. Papatheodorou, A. Bounovas, and E. Maltezos, “Tissue and swab culture in diabetic foot infections: neuropathic versus neuroischemic ulcers,” The International Journal of Lower Extremity Wounds, vol. 12, no. 2, pp. 87–93, 2013. View at Publisher · View at Google Scholar
  22. N. Papanas, A. J. Boulton, R. A. Malik et al., “A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy,” Diabetic Medicine, vol. 30, no. 5, pp. 525–534, 2013. View at Publisher · View at Google Scholar
  23. B. T. Altura and B. M. Altura, “Endothelium-dependent relaxation in coronary arteries requires magnesium ions,” British Journal of Pharmacology, vol. 91, no. 3, pp. 449–451, 1987. View at Google Scholar · View at Scopus
  24. N. Shao, H. Y. Kuang, N. Wang et al., “Relationship between oxidant/antioxidant markers and severity of microalbuminuria in the early stage of nephropathy in type 2 diabetic patients,” Journal of Diabetes Research, vol. 2013, Article ID 232404, 6 pages, 2013. View at Publisher · View at Google Scholar
  25. I. Gouni-Berthold, N. Papanas, and E. Maltezos, “The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with Non-Alcoholic Fatty Liver Disease,” Current Pharmaceutical Design. In press.
  26. Y. Amano, T. Yamaguchi, K. Ohno et al., “Structural basis for telmisartan-mediated partial activation of PPAR gamma,” Hypertension Research, vol. 35, no. 7, pp. 715–719, 2012. View at Google Scholar
  27. N. Papanas, P. Steiropoulos, E. Nena et al., “Predictors of obstructive sleep apnea in males with metabolic syndrome,” Vascular Health and Risk Management, vol. 6, no. 1, pp. 281–286, 2010. View at Google Scholar · View at Scopus
  28. E. Nena, P. Steiropoulos, N. Papanas et al., “Sleepiness as a marker of glucose deregulation in obstructive sleep apnea,” Sleep and Breathing, vol. 16, no. 1, pp. 181–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Michailidis, P. Steiropoulos, E. Nena, N. Papanas, E. Maltezos, and D. Bouros, “Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea,” The Open Cardiovascular Medicine Journal, vol. 5, no. 1, pp. 231–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Georgakarakos, N. Papanas, E. Papadaki, G. S. Georgiadis, E. Maltezos, and M. K. Lazarides, “Endovascular treatment of critical ischemia in the diabetic foot: new thresholds, new anatomies,” Angiology, vol. 64, no. 8, pp. 583–591, 2013. View at Publisher · View at Google Scholar